Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Nov;57(11):5707-9.
doi: 10.1128/AAC.01404-13. Epub 2013 Aug 12.

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012

A Walkty  1 , J A Karlowsky, H Adam, M Baxter, P Lagacé-Wiens, D J Hoban, G G Zhanel
Affiliations
Multicenter Study

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012

A Walkty et al. Antimicrob Agents Chemother. 2013 Nov.

Abstract

The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90 values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90 than that for ceftazidime). Eighty-nine percent (141/158) of multidrug-resistant isolates were inhibited by ≤8 μg/ml of ceftolozane-tazobactam.

PubMed Disclaimer

References

    1. Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, Canadian Antimicrobial Resistance Alliance, Hoban DJ 2010. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob. Agents Chemother. 54:4684–4693 - PMC - PubMed
    1. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848–854 - PubMed
    1. Biedenbach DJ, Moet GJ, Jones RN. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream isolates from the SENTRY antimicrobial surveillance program (1997–2002). Diagn. Microbiol. Infect. Dis. 50:59–69 - PubMed
    1. Mathai D, Jones RN, Pfaller MA, Participant Group North America SENTRY 2001. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America). Diagn. Microbiol. Infect. Dis. 40:129–136 - PubMed
    1. Walkty A, Baxter M, Adam H, Karlowsky JA, Lagace-Wiens P, Hoban DJ, Zhanel GG. 2012. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008–2011. Diagn. Microbiol. Infect. Dis. 73:361–364 - PubMed

Publication types

MeSH terms